Inhibrx Biosciences Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jul '26 Jul 14, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Market Cap	1,368	1,152	223	1,800	1,073	1,703
Market Cap Growth	554.66%	416.59%	-87.61%	67.69%	-36.96%	36.95%
Enterprise Value	1,387	1,134	78.38	1,732	1,007	1,649
Last Close Price	93.21	79.00	15.40	38.00	24.64	43.67
PE Ratio	-	-	0.14	-	-	-
Forward PE	-	0.20	0.20	-	-	-
PS Ratio	1051.92	885.87	1114.64	1000.02	489.70	235.48
PB Ratio	-	144.08	1.67	41.38	18.49	32.51
P/TBV Ratio	-	153.07	1.73	10.29	17.02	31.69
EV/Sales Ratio	1066.72	872.63	391.91	962.37	459.24	227.99
Debt / Equity Ratio	-8.49	13.10	0.05	4.78	3.54	1.44
Net Debt / Equity Ratio	-0.91	-2.15	-1.08	-1.56	-1.15	-1.03
Net Debt / EBITDA Ratio	-0.16	0.13	0.44	0.31	0.52	0.72
Net Debt / FCF Ratio	-0.15	0.13	0.73	0.34	0.58	0.67
Asset Turnover	-	0.01	0.00	0.01	0.01	0.05
Quick Ratio	6.10	3.68	3.76	4.95	9.94	5.89
Current Ratio	6.46	3.93	3.94	5.25	10.17	6.20
Return on Equity (ROE)	1996.40%	-197.85%	1905.92%	-475.31%	-263.00%	-127.91%
Return on Assets (ROA)	-74.48%	-82.52%	-135.66%	-73.22%	-58.51%	-52.05%
Return on Capital Employed (ROCE)	-91.10%	-106.86%	-169.27%	-85.15%	-65.99%	-63.71%
Earnings Yield	-	-	731.30%	-	-	-
Buyback Yield / Dilution	-0.49%	-3.36%	-27.17%	70.62%	-5.52%	-50.47%
Total Shareholder Return	-0.49%	-3.36%	-27.17%	70.62%	-5.52%	-50.47%

SEC Filings: 10-K · 10-Q